Rapport bénéfice–risque de l’association anticoagulants oraux et antiagrégants plaquettaires chez le sujet âgé : revue de la littérature

Ferrieres, 2007, Épidemiologie du syndrome coronaire aigu en France[[fr]]Epidemiology of acute coronary syndrome in France, Ann Cardiol Angeiol (Paris), 56, S8, 10.1016/S0003-3928(07)80021-7 Delluc, 2012, Épidemiologie et facteurs de risque de la maladie veineuse thromboembolique, Rev Mal Respir, 29, 254, 10.1016/j.rmr.2011.12.001 Fang, 2007, Atrial fibrillation in the elderly, Am J Med, 120, 481, 10.1016/j.amjmed.2007.01.026 Smith, 2006, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart Lung, and Blood Institute, Circulation, 113, 2363, 10.1161/CIRCULATIONAHA.106.174516 Pearson, 2002, Circulation, 106, 388, 10.1161/01.CIR.0000020190.45892.75 Mismetti, 2010, Recommandations de bonne pratique : prévention et traitement de la maladie thrombo-embolique veineuse en médecine, J Mal Vasc, 35, 127, 10.1016/j.jmv.2009.12.002 Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1 Chen, 2005, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1607, 10.1016/S0140-6736(05)67660-X Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Mehta, 2000, The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, Eur Heart J, 21, 2033, 10.1053/euhj.2000.2474 Fuster, 2006, Circulation, 114, e257, 10.1161/CIRCULATIONAHA.106.177292 Fang, 2004, Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation, Ann Intern Med, 141, 745, 10.7326/0003-4819-141-10-200411160-00005 Beyth, 1998, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am J Med, 105, 91, 10.1016/S0002-9343(98)00198-3 Forfar, 1979, A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment, Br Heart J, 42, 128, 10.1136/hrt.42.2.128 Gurwitz, 1988, Age-related risks of long-term oral anticoagulant therapy, Arch Intern Med, 148, 1733, 10.1001/archinte.1988.00380080037012 Levine, 2001, Hemorrhagic complications of anticoagulant treatment, Chest, 119, 108S, 10.1378/chest.119.1_suppl.108S Palareti, 1996, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy, Lancet, 348, 423, 10.1016/S0140-6736(96)01109-9 Van der Meer, 1993, Bleeding complications in oral anticoagulant therapy. An analysis of risk factors, Arch Intern Med, 153, 1557, 10.1001/archinte.1993.00410130073007 Guo, 2010, Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?, Clin Interv Aging, 5, 157, 10.2147/CIA.S9399 Capodanno, 2010, Antithrombotic therapy in the elderly, J Am Coll Cardiol, 56, 1683, 10.1016/j.jacc.2010.04.063 Lip, 2011, Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation, Am J Med, 124, 111, 10.1016/j.amjmed.2010.05.007 The Stroke Prevention in Atrial Fibrillation Investigators, 1996, Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial, Lancet, 348, 633, 10.1016/S0140-6736(96)03487-3 Lechat, 2001, Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane ; FFAACS), Cerebrovasc Dis, 12, 245, 10.1159/000047711 Gullov, 1999, Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation, Arch Intern Med, 159, 1322, 10.1001/archinte.159.12.1322 Shireman, 2004, Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients, Stroke, 35, 2362, 10.1161/01.STR.0000141933.75462.c2 Hansen, 2010, Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation, Arch Intern Med, 170, 1433, 10.1001/archinternmed.2010.271 Huynh, 2001, Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery, Circulation, 103, 3069, 10.1161/01.CIR.103.25.3069 Herlitz, 2004, Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study, Eur Heart J, 25, 232, 10.1016/j.ehj.2003.10.026 Buresly, 2005, Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction, Arch Intern Med, 165, 784, 10.1001/archinte.165.7.784 Ruiz-Nodar, 2008, Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis, J Am Coll Cardiol, 51, 818, 10.1016/j.jacc.2007.11.035 Larson, 2004, Should aspirin be continued in patients started on warfarin?, J Gen Intern Med, 19, 879, 10.1111/j.1525-1497.2004.30419.x Andreotti, 2006, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated comprehensive meta-analysis of 25,307 patients, Eur Heart J, 27, 519, 10.1093/eurheartj/ehi485 The Stroke Prevention in Atrial Fibrillation Investigators, 1996, Bleeding during antithrombotic therapy in patients with atrial fibrillation, Arch Intern Med, 156, 409, 10.1001/archinte.1996.00440040081009 Pengo, 1998, Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation, Am J Cardiol, 82, 433, 10.1016/S0002-9149(98)00357-9 Anderson, 2007, Circulation, 116, e148, 10.1161/CIRCULATIONAHA.107.181940 Paikin, 2011, Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials, Blood Rev, 25, 123, 10.1016/j.blre.2011.01.007 Dentali, 2007, Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials, Arch Intern Med, 167, 117, 10.1001/archinte.167.2.117 Palareti, 2000, Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study, Arch Intern Med, 160, 470, 10.1001/archinte.160.4.470 Fihn, 1996, The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics, Ann Intern Med, 124, 970, 10.7326/0003-4819-124-11-199606010-00004 Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 Lip, 2010, Improving stroke risk stratification in atrial fibrillation, Am J Med, 123, 484, 10.1016/j.amjmed.2009.12.013 Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation, Chest, 137, 263, 10.1378/chest.09-1584 Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J, 151, 713, 10.1016/j.ahj.2005.04.017 Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 Kuijer, 1999, Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism, Arch Intern Med, 159, 457, 10.1001/archinte.159.5.457 Moroney, 1999, Treatment for the secondary prevention of stroke in older patients: the influence of dementia status, J Am Geriatr Soc, 47, 824, 10.1111/j.1532-5415.1999.tb03839.x Man-Son-Hing, 1999, Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med, 159, 677, 10.1001/archinte.159.7.677 Gage, 2005, Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall, Am J Med, 118, 612, 10.1016/j.amjmed.2005.02.022 Alexander, 2009, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, Circulation, 119, 2877, 10.1161/CIRCULATIONAHA.108.832139 Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819 Mega, 2009, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, Lancet, 374, 29, 10.1016/S0140-6736(09)60738-8 Fitchett, 2012, Potential role of rivaroxaban in patients with acute coronary syndrome, Drug Design Dev Ther, 6, 349, 10.2147/DDDT.S30342 Amin, 2013, Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies, Clin Interv Aging, 8, 75, 10.2147/CIA.S37818 Goutelle, 2012, Choix d’une formule d’estimation de la fonction rénale pour adapter la posologie des médicaments chez les sujets âgés. Commentaires sur l’article de Andro et al, Rev Med Interne, 33, 350, 10.1016/j.revmed.2012.03.360 Devereaux, 2001, Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study, BMJ, 323, 1218, 10.1136/bmj.323.7323.1218 Brophy, 2004, Anticoagulant use for atrial fibrillation in the elderly, J Am Geriatr Soc, 52, 1151, 10.1111/j.1532-5415.2004.52314.x Friberg, 2006, Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study), Eur Heart J, 27, 1954, 10.1093/eurheartj/ehl146 Belch, 2008, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, BMJ, 337, a1840, 10.1136/bmj.a1840 Berger, 2011, Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials, Am Heart J, 162, 115e2, 10.1016/j.ahj.2011.04.006 Beyth, 2000, A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial, Ann Intern Med, 133, 687, 10.7326/0003-4819-133-9-200011070-00010 Leger, 2004, Impact d’un programme d’éducation thérapeutique sur les attitudes de prévention vis-à-vis du risque iatrogène : étude pilote controlée visant les patients sous anticoagulants oraux pour maladie thromboembolique veineuse, J Mal Vasc, 29, 152, 10.1016/S0398-0499(04)96737-6 Satger, 2009, Éducation thérapeutique des patients traités par anticoagulants oraux antivitamines K, Presse Med, 38, 1780, 10.1016/j.lpm.2009.07.019